editedbook
Publication: IIP Proceedings Year: 2022, Month: November Page No: 229-241, ISSN/ISBN: 978-93-95632-92-8, DOI/Link: https://rsquarel.org/assets/docupload/rsl2023533C9BF277ABFC5.pdf
POTENTIAL OF GLUCAGON LIKE PEPTIDE-I IN THE THERAPYOF OBESITY IN ASSOCIATION WITH METABOLIC SYNDROME
Area/Stream: Medical Sciences, Authors: Kinnera Ratna Sri Ganapathineedi, M. Ganga Raju Keywords: Glucagon like peptide-1(GLP-1) metabolic syndrome, obesity, Type II diabetes mellitus and cardiovascular diseases Book Name /series: Futuristic Trends in Medical Sciences ,Volume 2, Book 21, Part 2, Chapter 6Publication: IIP Proceedings Year: 2022, Month: November Page No: 229-241, ISSN/ISBN: 978-93-95632-92-8, DOI/Link: https://rsquarel.org/assets/docupload/rsl2023533C9BF277ABFC5.pdf
Abstract:
Obesity and associated metabolic syndrome (type 2 diabetes mellitus and heart diseases) are one of the main reasons of death globally. Several drugs are currently approved and available in the market for obesity, type II diabetes mellitus and cardiovascular diseases. But, targeting a specific receptor which can potentially reduce obesity and associated metabolic syndrome will be helpful in future therapy. Current review mainly focuses on the possible mechanistic role of glucagon like peptide-1 (GLP-1), its agonists and glucagon like peptide-1 receptor (GLP1R) in the treatment of obesity and associated metabolic syndrome for future consideration.
Cite this: Kinnera Ratna Sri Ganapathineedi, M. Ganga Raju,"POTENTIAL OF GLUCAGON LIKE PEPTIDE-I IN THE THERAPYOF OBESITY IN ASSOCIATION WITH METABOLIC SYNDROME", Futuristic Trends in Medical Sciences ,Volume 2, Book 21, Part 2, Chapter 6, November, 2022, 229-241, 978-93-95632-92-8, https://rsquarel.org/assets/docupload/rsl2023533C9BF277ABFC5.pdf
Views: 4181
Download File
News
